Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain

Sponsor
Sanofi
Study ID
NCT06415175
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
6 Months - 11 Years
Healthy Volunteers
Not accepted

Interventions

  • Dupilumab — DRUG
    This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.

Study Details

This is a multicentre, prospective, non-interventional study that aims to describe the treatment patterns of in Atopic dermatitis (AD) patients aged 6 months to 11 years old in Spain: patients' characteristics, disease characteristics, prior treatments for and treatment prescription modalities. As well as to document the real-world effectiveness and safety of dupilumab during the two years of follow up. No diagnostic or therapeutic intervention outside of routine clinical practice will be applied.

Key Dates

Start date
Nov 14, 2024
Status verified
Feb 2026
Primary completion
Sep 30, 2026
Completion
Nov 23, 2027

Study Design

Enrollment
143 participants (actual)

Arms

  • Arm: Dupilumab
    The information will be collected during consultation as part of the patient's usual follow-up.

Primary Outcome Measure

Demographic characteristic of pediatric patients initiating treatment with dupilumab for Severe AD: Age [ Time Frame: At baseline ]

Related Studies